Individualising care – considerations in the escalation of pharmacological management of type 2 diabetes - Certificate of Completion
Attaining optimal blood glucose management in patients with type 2 diabetes is important to improve both short-term and long-term health outcomes. A sustained legacy effect of intensive glucose-management in type 2 diabetes has been observed, indicating a continued reduction in microvascular risk. In addition, the legacy effect demonstrates an association between intensive glucose management and a significantly decreased risk of myocardial infarction and death.
A general glycaemic target of HbA1c = 7% (53mmol/mol) has therefore been recommended for newly diagnosed and uncomplicated patients. Over 60% of patients, however, are reported as not achieving their glycaemic goals. One Australian study showed less than half of patients with type 2 diabetes seen in general practice had an HbA1c = 7% (53 mmol/mol) with 25% having an HbA1c > 8% (64mmol/mol). Current glycaemic management seems to be “missing the target” of accepted treatment goals.
This interactive online learning activity is valued at 2 Hour(s) of continuing education.
John Eric Barlow
Clinical Supervisor, University of Notre Dame, NSW
Surgical Assistant Strathfield Private Hospital, NSW
Westmead Private Hospital, NSW
APD, CDE, BHSc (Nut&Diet), MSc (Diabetes)
Professional Services Manager
Australian Diabetes Educators Association
Après avoir terminé le programme, les participants seront en mesure :
- de décrire les caractéristiques cliniques de la maladie pulmonaire obstructive chronique (MPOC)
- de décrire la prise en charge non pharmacologique et pharmacologique de la MPOC
- de résumer les recommandations de l'énoncé de position 2017 de la Société canadienne de thoracologie (SCT) sur la pharmacothérapie pour la MPOC
- de discuter de la place du traitement combiné par inhalation triple dans la prise en charge pharmacologique de la MPOC